Veytics Intelligence
2026-10-14 · NASDAQ

AbbVie's Subcutaneous Skyrizi Shows Endoscopic Benefits In Crohn's Diseases

(RTTNews) - Tuesday, AbbVie reported new Phase 3 AFFIRM data showcasing endoscopic outcomes with subcutaneous Skyrizi in adults with moderately to severely active Crohn's disease.

Doc ban tin day du cua Veytics

Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.